Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Synthetic high-density lipoprotein (sHDL) nanoparticles composed of apolipoprotein A-I (ApoA-I) mimetic peptide and phospholipids have been shown to reduce atherosclerosis in animal models.
|
31776208 |
2020 |
Arteriosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Familial apolipoprotein A-I (apoA-I) deficiency (FAID) involving low levels of both apoA-I and high-density lipoprotein (HDL) cholesterol is associated with accelerated atherosclerosis.
|
31003938 |
2020 |
Arteriosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In previous work, we reported that helper-dependent adenoviral (HDAd) overexpression of apolipoprotein A-I (apoAI) in endothelial cells (ECs) increases cholesterol efflux in vitro and reduces atherosclerosis in vivo.
|
30079772 |
2019 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
For the current analyses, baseline (2000-2002) plasma total apoC-III and apolipoprotein A-I concentrations of HDL containing or lacking apoC-III were newly measured via sandwich ELISA in 4579 participants from the Multi-Ethnic Study of Atherosclerosis.
|
30949716 |
2019 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results indicate that the function of lipid-poor apoA-I is not limited to the efflux of cholesterol and phospholipids but suggest that apoA-I serves as a major regulator of the foam cell lipidome and might play an important role in reducing multiple lipid species involved in the pathogenesis of atherosclerosis.
|
31382484 |
2019 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Consistent with these findings, animal studies revealed that the capacity of HDL to acquire cholesterol upon lipolysis was reduced in low HDL-C apolipoprotein A-I knock-out mice and was negatively correlated with aortic accumulation of [<sup>3</sup>H]-cholesterol after oral gavage, attesting this functional characteristic as a negative metric of postprandial atherosclerosis.
|
31840535 |
2019 |
Arteriosclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The presence of a damaging mutation in ABCA1 or APOA1 confers an increased risk of atherosclerosis relative to patients without such a mutation at a comparable level of HDL cholesterol, possibly because of a reduction in CEC.
|
29150341 |
2019 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein A-I (apoA-I), a major component of HDL helps in reverse cholesterol transport, whose function is greatly affected during atherosclerosis due to oxidation by myeloperoxidase.
|
31386835 |
2019 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?
|
29423541 |
2018 |
Arteriosclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
These results argue for a protective effect of EGCG on apoA-I amyloid associated with atherosclerosis and suggest that EGCG-induced remodeling of amyloid may be tightly regulated by GAGs and other amyloid co-factors <i>in vivo</i>, depending on EGCG bioavailability.
|
29853648 |
2018 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
It has been identified that apolipoprotein A1 (ApoA-I) obstructs TGF-β1-induced endothelial dysfunction, providing a protective effect for ECs and also anti-AS activity.
|
28434000 |
2018 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study.
|
29582212 |
2018 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Animal studies suggest that administration of apolipoprotein A-I, the main protein constituent of HDL, can prevent transplant arteriosclerosis. apoA-I administration increases CEC of HDL.
|
29337706 |
2018 |
Arteriosclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits.
|
29122817 |
2018 |
Arteriosclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We examined how point mutations associated with hereditary amyloidosis (F71Y and L170P) or atherosclerosis (L159R) influence the local apoA-I conformation in model lipoproteins.
|
30004693 |
2018 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
HDL-ApoA1 plays a pivotal role in the prevention of atherosclerosis and cardiovascular diseases.
|
29248767 |
2018 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Unlike in the adult population, serum ApoA-1, ApoB, and ApoB/ApoA-1 ratio may not have significant advantage over conventional lipoproteins in evaluating the presence of systemic inflammation, MS, and risk of atherosclerosis in obese adolescents.
|
29154726 |
2018 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein A-I (ApoA-I), which recently attracted great attention as an important protein related to the increasing risk of various cancers, is a factor closely related to metabolic diseases such as ardiovascular diseases and atherosclerosis.
|
30410356 |
2018 |
Arteriosclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Serum amyloid A protein (SAA) is known as an inflammatory factor and an apolipoprotein that can replace apolipoprotein A-I/II components as the major apolipoprotein of high-density lipoprotein (HDL), which is related to atherosclerosis.
|
28870546 |
2017 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein A-I Modulates Atherosclerosis Through Lymphatic Vessel-Dependent Mechanisms in Mice.
|
28939717 |
2017 |
Arteriosclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Genome wide association study (GWAS) studies in humans and hybrid mouse diversity panel (HMDP) studies looking for genetic variants associated with apoA-I or HDL cholesterol levels with cardiovascular disease and atherosclerosis have not provided strong evidence for their atheroprotective function.
|
28731861 |
2017 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Treatment with the monoclonal antibody E06 or with apolipoprotein A-I mimetic peptide D-4F, capturing OxPAPC in atherosclerosis, prevented inflammatory hyperalgesia, and in vitro TRPA1 activation.
|
28710476 |
2017 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The potential benefits of high-density lipoproteins (HDL) against atherosclerosis are attributed to its major protein component, apolipoprotein A-I (apoA-I).
|
28167355 |
2017 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
ApoA-I-Milano (M) is a mutated variant, which showed increased vasoprotective properties compared to ApoA-I-wild type in models of atherosclerosis and cardiovascular damage.
|
28941727 |
2017 |
Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
HIV(+)HDL known to have reduced antioxidant function and rate of HDL/ApoA1 exchange promoted MDFCF to a greater extent than HDL(-)HDL (33.0 vs. 26.2% foam cells.Subject codes: Inflammation, Lipids and Cholesterol, Vascular Biology, Oxidant Stress, Atherosclerosis.
|
28926407 |
2017 |